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Abstract 
Common local anaesthetics such as lidocaine are administered by the hypodermic parenteral 
route but it causes pain or anxiety to patients. Alternatively, an ointment formulation may be 
applied which involves a slow drug diffusion process. In addressing these two issues, this paper 
aims to understand the significance of the ‘poke and patch’ microneedle (MN) treatment on skin 
in conjunction to the lidocaine permeation, and in particular, the vertical (depth averaged) and 
horizontal (e.g., lateral) permeation profiles of the drug in skin. The instantaneous 
pharmacokinetics of lidocaine in skin was determined by a skin denaturation technique coupled 
with Franz diffusion cell measurements of the drug pharmacokinetics. All pharmacokinetic 
profiles were performed periodically on porcine skin. Three MN insertion forces of 3.9, 7.9, and 
15.7 N were applied on the MN to pierce the skin. For the smaller force (3.9 N), post MN treated 
skin seems to provide an ‘optimum’ percutaneous delivery rate. A 10.2 fold increase in lidocaine 
permeation was observed for a MN insertion force of 3.9 N at 0.25 h and similarly a 5.4 fold 
increase in permeation occurred at 0.5 h compared to passive diffusional delivery. It is shown 
that lidocaine permeates horizontally beyond the area of the MN treated skin for the smaller MN 
insertion forces, namely, 3.9 and 7.9 N from 0.25 to 0.75 hours, respectively. The lateral 
diffusion/permeation of lidocaine for larger MN treated force (namely, 15.7 N in this work) 
seems to be insignificant at all recorded timings. The MN insertion force of 15.7 N resulted in 
lidocaine concentrations slightly greater than control (passive diffusion) but significantly less 
than 3.9 and 7.9 N impact force treatments on skin. We believe this likelihood is due to the skin 
compression effect that inhibits diffusion until the skin had time to relax at which point lidocaine 
levels increase. 
Key words: Microneedle, Percutaneous Delivery, Depth averaged permeation, Lateral 
permeation, Lidocaine, Skin 
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INTRODUCTION  
Lidocaine hydrochloride, to be called as lidocaine herein, is a drug which is used as a local 
anaesthetic for superficial skin wounds [1, 2]. Traditionally, lidocaine is delivered by hypodermic 
injection for parenteral administration. This causes pain and often trepidation coupled with 
patient phobia, which may obstruct the successful delivery of the drug [3, 4]. Other traditional 
methods of lidocaine delivery involve the use of topical ointment (e.g., AnestenTM, Haim 
International, Seoul, Korea) and transdermal patch (e.g., Lidoderm® patch [5]). However, they 
have a disadvantage of taking a longer time for the drug to diffuse into the dermis layer through 
the stratum corneum (SC) layer of skin [6]. In percutaneous lidocaine delivery, the formidable 
challenge is to bypass the SC. This layer is 10-15µm thick and it is the skin’s uppermost barrier 
to foreign particulate entry into skin [7, 8]. 
In general, the mass flux due to diffusion of drug molecules through the SC is affected by the 
molecular hydrophilicity and the concentration gradient across different skin depths [9]. Franz 
diffusion cell (FDC) is typically adopted to determine the in vitro (IV) mass transport properties 
of the active molecules passing the SC [10] or the whole skin thickness [11,12]. Depending on 
the direction of concentration gradient and permeability, an active molecule can however diffuse 
both vertically and horizontally in skin tissues. In the present context, horizontal permeation is 
taken in a broad sense. It may imply both lateral and transverse permeation in a Cartesian co-
ordinate system or radially for circular co-ordinate system. 
The migration of the active molecules due to a concentration gradient from the skin surface is 
the most commonly accepted IV vertical (depth averaged) transdermal delivery bypassing the 
viable epidermis (VE) and dermis layer before appearing into the receptor compartments of 
FDC. In a similar manner, the horizontal permeation of the drug molecules in IV skin biopsy can 
be a direct technique for quantifying the drug transport in the lateral (x-direction), transverse (y-
direction) or radial (r-direction) directions at different distances from an epicentre of the skin 
(Figure 1a) provided the drug transport can be determined. In the case of MN treated skin, e.g., 
‘poke and patch’ type delivery [13], the origin of a drug can be the outermost (e.g., skin surface) 
and/or the inner locations of the skin (e.g., microcavity). As far as we are aware, there are few 
or no studies relating to the migration of a drug molecule in both vertical and horizontal 
directions in MN pierced skin, and in particular, lidocaine delivery using MNs. This issue can be 
particularly important for distribution of lidocaine delivered in skin.   
Skin can be interpreted as a complex hydrophobic membrane because of the inherent barrier 
property against most exogenous molecules. In most cases, small, hydrophobic molecules 
migrate by intracellular and intercellular routes inside skin. At a given time, biopsied sections of 
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the skin can be homogenised and denatured for the purpose of disrupting the skin tissue 
structure and releasing the active molecules into sample vials for determining their 
concentrations, e.g., analyses using high performance liquid chromatography (HPLC) [14]. The 
homogenisation and denaturing of skin is discussed further in this manuscript.  
In a number of recent studies, it has been discussed that MN assisted percutaneous delivery of 
lidocaine may be beneficial in numbing a larger surface area of skin and minimising possible 
clearance from predominate vertical permeation of the drug [11,12,15,16]. Parenteral 
administration of lidocaine may increase the chances of clearance resulting in its depleted 
levels in the systemic circulation [17]. Lidocaine is metabolised in the systemic circulation by 
various enzymes, and additional medications such as statins and chemotherapeutic agents can 
potentially increase the clearance of lidocaine influenced by the metabolism [18,19]. 
Furthermore, the diffusion of hydrophobic and hydrophilic molecules in SC layer has been 
reported to be faster laterally than vertically across the skin because of the continuous nature of 
the intercellular pathway [20, 21]. As far as we know there is only one reported experimental 
study on horizontal permeation of lidocaine in full thickness skin [15]. In this study, a method of 
dip coating MNs with lidocaine and single patch application was attempted. After skin samples 
were enzymatically digested, it was found that therapeutic thresholds could be sustained for 
short durations and higher lidocaine concentrations could be obtained for longer durations when 
combined with a vasoconstrictor epinephrine after treatment with dip coated liquid crystalline 
polymer MNs [15]. 
As a drug delivery method, MNs have been reviewed significantly in the literature and therefore 
they are not discussed in length in this paper [22-24]. The MNs can be constructed from silicon, 
metals or polymers [9, 22, 25]. In principle, they should pierce past the SC layer to form micro 
cavities in skin before drug application or pre-loaded with drugs at the point of application. In 
other cases the MNs dissolve once in the skin releasing the drug to allow increased permeation 
rates [26]. The resealing time of MN induced cavities in skin has evoked interest when 
considering the poke and patch technique [13] and, drug pharmacokinetic thresholds have been 
found to be affected when pore closure is considered. For example, Brogden et al. [27] 
expressed the half-life of pore closure from placebo MNs at 18.2 hours and 87.5-97% of micro-
cavities were closed between 54.7-91.2 hours. In the case of lidocaine application with the help 
of MN, time duration of 45 minutes to 1 hour may be short in attempting to relate the possible 
effects on pore closure time with micro-cavity drug permeation; however, there is little or no 
evidence in this regards at the moment. 
Recently, a lidocaine sodium carboxymethyl cellulose/gelatine (NaCMC/gel) bipolymeric 
formulation has been suggested for controlled permeation of lidocaine in MN pierced skin [11, 
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12] where the authors have used a ‘poke and patch’ approach for percutaneous delivery of 
lidocaine. Subsequently, the permeation profiles of the MN pierced skin for various mass ratios 
of NaCMC/Gel with lidocaine were determined. The MN pierced skin showed faster lidocaine 
permeation than untreated MN skin for vertical layer skin profiles. Lidocaine was released into 
the skin from the formulation and it bypassed the SC layer because of the MN cavities. 
Furthermore, the physico-chemical properties of the formulations, loading efficiency, zeta 
potential, mean particle size and morphology have been studied. In principle, the MN treatment 
of skin allows further increase in the efficacy of lidocaine permeation as well as controlled 
spreading of the drug formulation along the skin surface as demonstrated in the above studies. 
In general, homogenisation of skin adopts mechanical forces of shearing and compression of 
skin into shredded tissue components. For example, a rotor component of a rotor/stator 
homogeniser may be used which creates low pressure areas, moving suspension material (e.g., 
skin tissue debris) towards a sub-500 µm gap between the rotor and stator, shearing any 
trapped suspension material [28]. However, the adaptation of a rotor/stator homogeniser is 
unsuitable for shredding dissected thin skin slices below 500 μm thickness. This is due to the 
skin not being properly sheared if it enters and exits the rotor/stator. An alternative homogeniser 
is a glass tissue grinder (e.g., constructed from Teflon) and comprising of a specialist mortar 
test tube [29]. Sharp blade based shear homogenisation is not a regular process for skin tissue 
samples despite not requiring external power sources. An example application of this can be 
found in cutting of porcine ear tissue before denaturation by dimethylsulfoxide solution (DMSO) 
[14]. 
Another method which involves the pestle and mortar skin homogenisation [30] without the 
need for direct current (DC) or alternating current (AC) supply was adopted in our study. There 
have been a relatively small number of publications outlining the details of this technique for 
skin homogenisation prior to drug quantification in skin layers. Conceptually, the method aims to 
increase the amount of ruptured cells and dissemble the organised cell packing in skin tissues 
randomly. There is a likelihood of tissue sections that have not been exposed to sufficient shear 
forces. Therefore, this alone cannot suffice for the purpose of drug detection and, hence, a 
second step of cellular denaturation is required to release the drug molecules for subsequent 
detection. The second stage of enzymatic protein denaturation of skin specimens are outlined in 
examples of quantification of hydroxyproline as a byproduct of α-chymotrypsin hydrolysis from 
fragmented collagen [31] and the quantification of combined chemical enhancers such as 5-
aminolevulinic acid with glycerol monooleate in epidermal skin delivery [32]. However, diode 
array detection and peak area quantification of active macromolecules eluting at similar 
detection wavelengths ranges to enzyme and skin protein by products is unachievable by liquid 
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chromatography-diode array (LC-DA) analysis alone. Therefore, heat denaturation technique 
may be used.  
High temperatures above 50˚C for a long period allow for intra and extracellular denaturation of 
skin proteins [33]. Denaturation temperature of human skin at 38.5˚C allows the appearance of 
imino acid residues in protein breakdown (222 imino residue parts per 1000 part amino acids) 
[34]. Collagen based porcine skin has a denaturation temperature of 37˚C [35, 36]. Also, dry 
heating (e.g., a thermal effect generated by passing hot air) at temperature ranging from 100˚C 
to 315˚C on skin surfaces result in the weakening of mechanical properties and disorder of 
keratin network of the skin [37]. Adaptation of dry heat ablation of skin at high temperatures 
occurred during micro second time frames as longer durations would have denatured more skin 
proteins below the upper layers [37]. Also, prolonged dry heat ablation would burn skin into 
powdered carbon ash and lidocaine will be undetectable by LC-DA methods as the chemical 
structure would be changed completely. 
Keeping the above discussed points in mind, lidocaine permeation rates have been analysed in 
the vertical and horizontal directions in this paper specifically for lidocaine NaCMC/gel 
bipolymeric formulation. Alternatively to Zhang et al. [15] enzymatic denaturation technique, 
homogenisation followed by heat denaturation of the IV skin biopsy was performed to determine 
the horizontal permeation profile in the MN pierced skin (discussed below) while FDC was used 
to determine the vertical permeation profiles. For the purpose of this work a ‘poke and patch’ 
technique was adopted using fixed MN insertion forces [23, 25, 38] with the purpose to obtain 
reproducible artificial microcavities and to enhance the percutaneous lidocaine delivery in 
bypassing the SC layer of skin. Constant MN insertion forces from a pneumatic pressure based 
force device are applied and held for fixed time duration to allow the MNs to pierce the skin as 
uniformly as possible [23]. This also ensures that the MN cavities are formed so as to just pierce 
past the SC providing small MN holes for percutaneous drug delivery. 
In the context of this paper, we aim to relate the effects of MN insertion forces with the 
instantaneous pharmacokinetic distribution of lidocaine towards vertical (depth averaged) and 
horizontal permeation in skin. Ideally, the lag time for therapeutic level of lidocaine permeation 
needs to be the shortest possible for affecting the skin target region. Nevertheless, a sustained 
therapeutic level for upto 45 minutes is considered to be most ideal in numbing the area, for 
example, in the treatment of skin wounds or localised biopsy of abnormal skin tissue. 
Procedures such as ablative skin resurfacing requiring at least 60 minutes for uniform 
anaesthetic effect can potentially be shortened to 45 minutes duration maximum for regaining 
complete local sensation in the area and reducing patient waiting time [39]. Within this work, a 
method of measuring the vertical diffusion coefficient through porcine skin is also attempted. 
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This required first, the use of a FDC followed by centroid and diametric from centroid punching 
of the square sectioned skin which were subsequently homogenised mechanically and heat 
denatured.  
It is expected that this paper would allow better understanding of vertical and horizontal 
permeation of lidocaine in MN pierced skin.  
MATERIAL AND METHODS 
Materials 
Gelatin (Porcine, type A, Bloom 300), sodium carboxymethylcellulose (degree of substitution 
0.9; MW: 250 kD), lidocaine HCl (MW: 288.81 g/mol), sorbitan monooleate (SPAN 80), 
Glutaraldehyde (stock solution of 50% w/w), trifluoroacetic acid (>99 % assay) and paraffin 
liquid (density: 0.859 g/ml) were purchased from Sigma-Aldrich Ltd, Dorset, UK. Acetonitrile 
(HPLC grade, 99.8 % assay) and acetic acid (analytical grade, 99.8 % assay) were purchased 
from Fisher Scientific Ltd, Loughborough, UK). Essential materials for IV skin studies were 
porcine auricles (local butcher, Loughborough, UK), stainless steel MNs (AdminPatch®1200, 
nanoBioSciences PLC, California, USA) and FDCs (Logan Instruments Inc, ‘FDC-6’, New 
Jersey, USA) were already available.  
Preparation of Lidocaine NaCMC:gel microgels 
The optimum Lidocaine NaCMC:gel 1:2.3 microgels were prepared exactly as outlined from the 
methods stated in Nayak et al. [11]. The reason for choosing NaCMC:gel 1:2.3 as the optimum 
vehicle was due to the ideal physico-chemical properties outlined in Nayak et al. [11].   
Percentage loading efficiency 
The characterised percentage loading efficiency (LE) for our lidocaine microgel formulation 
(equation 2) was calculated as discussed earlier [11,12]  
%LE =  Actual 5% weight of Lidocaine from sample(g)
5% theoretical loaded weight of Lidocaine(g) × 100                                                        (2) 
A 5% of the mean total sample weight was used to save time in preparation of new batches of 
formulation for one set of tests. Lidocaine microgels formulated on a batch scale was a time 
consuming process and complete samples were not tested here. The lidocaine hydrogels were 
diluted with 20ml of ultrapure water as excess solvent heated to 40 ± 0.5 °C and sonicated 
(Branson Digital Sonifier 450, USA) at 15-20 W for 2 minutes. This allows lidocaine to dissolve 
in ultrapure water. Normal sonication frequencies cut approximately 24 hours’ maximum time 
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required to disrupt the electrostatic and covalently held microparticle interactions between 
NaCMC and gel by high temperature denaturation without boiling the drug [40]. The ‘dissolved 
lidocaine’ was filtered using Nylon 6,6 membranes of 0.1 μm pore size (Posidyne membranes, 
Pall Corporation, Portsmouth, UK) before quantification by HPLC analysis. 
Microgel morphology and microparticle diameters 
The morphology of lidocaine NaCMC:gel 1:2.3 microgels were observed under an optical 
microscope (Olympus BX43, Tokyo, Japan). Images of the microparticles were taken using a 
camera (Q imaging Retiga 2000R, Canada) and analysed using ImageJ software.  
In vitro permeation studies 
The amounts of lidocaine in the VE layer and systemic layer (receptor of FDC) were determined 
from IV studies. The pharmacokinetics was subsequently deduced from IV quantification for 
vertical and horizontal permeation of lidocaine assuming homogeneity of the VE layer for 
molecular diffusion, i.e., isotropic diffusion profiles [41].  
Skin preparation 
As recommended in Meyer et al. [42], whole porcine auricle squares of 4.0 cm2 were laterally 
thin sliced and the cartilage, connective tissue and fatty components were discarded. All visible 
hair was removed using scissors to minimise any obstruction with the placement of lidocaine 
microgel on skin. MNs (AdminPatch® 1200) were applied on the skin for upto 5 minutes. Each 
needle was preset to 1100 µm length with a MN density of 43 in one cm2 surface area. MNs 
fabricated at 1000μm length have the same pain scores (VAS) on human subjects in 
comparison to the borosilicate glass material extruded at 500µm length when a saline volume of 
upto 0.6 ml was delivered in the dermis layer of skin [43]. Normally, the entire length of MNs 
from base to tip does not penetrate the skin with the needle base touching the skin surface 
because of the elastic folding effect of skin [9]. A full thickness skin piercing using 1100 µm 
length MNs and the MNs density resulted in approximately 400 µm deep cavities [12]. However, 
we controlled the MN cavities to a much smaller length so as to just pierce the SC in this work 
as discussed below.  
Application of MN insertion force 
In order to ensure that uniform force is applied to pierce the skin, the MN patch was applied on 
the skin samples at 0.5, 1.0 and 2 bar pressures equating to forces of 3.9, 7.9 and 15.7 N, 
respectively. The minimum insertion force achievable using an in-house pressure/force device 
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[23] was 3.9 N. The three insertion forces adopted here were constant forces as a hypothetical 
standard if an applicator device were to be fabricated to insert the MNs into skin. Thumb 
pressure, as often done to insert MN on skin, was not applied as they may introduce some 
variability in the forces applied. Furthermore, the forces were chosen so as to just pierce the 
skin keeping in mind the percutaneous delivery of lidocaine where the MNs cavities are small 
rather than large which facilitate transdermal permeation of the drug. 
The insertion forces were applied via a vertically arranged pressure/force impact device (SMC 
pneumatics Ltd, Buckinghamshire, UK; serial: CD85N16-50-B) as adopted from Cheung et al. 
[20]. The insertion force was calculated using equation (1):  
 𝐹 = 𝑝𝑝𝑑2
4
                                        (1)            
Where F is the force (N), p is the pressure (N/mm2), and d is the piston bore diameter (mm). As 
the piston rod is lowered far down the cylinder compartment so that the punch unit touches the 
MN substrate, the outstroke impact of a double acting cylinder is the dominating force in a 
double acting pressure device [44]. Independent air pressures at 0.5-2 bar ranges were 
impacting on the bore area of the lowered piston rod. The bore area was contained inside a 
closed piston chamber so that compressed air could not escape the piston chamber and impact 
the tissue directly. Therefore, equation (1) is implemented in determining the vertical 
compression force.  
Dyeing of skin samples 
Skin samples were dyed to show qualitative MN piercing patterns through skin in plan (top) view 
as a quick method to determine if MNs have pierced the skin. As in IV studies, the device 
outlined by Cheung et al. [23] was used to treat skin samples at 3.9, 7.9 and 15.7 N for upto 5 ± 
0.1 min. Samples were observed after dyeing with a natural blue food colouring (Sainsbury’s, 
Loughborough, Leicestershire, UK ). 
Characterisation of microcavities 
Similar MN impact forces and time taken as mentioned in the previous section were subjected 
on the skin samples. The largest cross sectioned row of channels was viewed by micro-
dissecting strips in plane to MN path as shown in Figure 1b. An image of a MN patch 
(AdminPatch®) adopted for the poke and patch method throughout this study is shown in Figure 
1c. The samples were then cryotomed (5 µm), dyed in methylene blue solution (0.5 % w/v) 
(Sigma Aldrich, Dorset, UK), observed under the microscope (Ceti S035, Chalgrove, 
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Oxfordshire, UK) and scaled using an image processing software (ImageJ, National Institute of 
Health (NIH), USA) with a certified graticule. Unlike in the previous method of using proprietary 
food colouring, the distinct blue colour density between SC and VE layer can only be observed 
by methylene blue dye. Methodology for this was adapted from Chueng et al. [23]. Additionally, 
flash freezing was adopted to preserve pierced holes created as compared with slow 24 hour 
freezing at -30˚C in a cryotome. 
As stated above, the SC layer is accepted to be the topmost (first) ~15µm thick skin layer in 
accordance with literature (e.g., Sivamani et al. [8]). It was also confirmed by dissecting 5µm 
transverse slices of skin and studying under the microscope after dying the skin surface with 
methylene blue solution (0.5 % w/v) (Sigma-Adrich Ltd, Dorset, UK). The recommended 
concentration of methylene blue solution and the approximate time in allowing dye diffusion 
through skin was adopted from Singh and Banga [45] and Kalluri and Banga [46].  
Permeation Study 
Lidocaine permeation studies were performed using MN treated skin, which were compared 
with passive permeation profiles of the drug. Lidocaine NaCMC:gel 1:2.3 microgel (0.1 ± 0.02g) 
droplet was added on an epicentre skin surface before clamping onto a FDC (FDC-6). The 
amount of lidocaine loaded in the microgel was 2.44 % wt. The surface area of the FDC 
receptor orifice was 0.679 cm2. Lidocaine formulations were dispensed on the epicentre of the 
skin (Figure 1a) [11,12]. The receptor compartment of the FDC contained deionised (DI) water 
set at 37 ± 0.5°C in order to mimic physiological temperature in of plasma rich systemic layer. 
The total receptor volume was 5.0 ± 0.025 ml.  Receptor volumes (1.5 ± 0.5 ml) were removed 
at 0.25 hour intervals. The total duration of IV study was one hour. After the FDC experiments, 
the epicentre and diametrically opposite regions of the skin was biopsied (Figure 1a) (RS 
International, Nottinghamshire, UK). The epidermis of punched skin was temporarily bonded 
using Cryo-M-bed inert glue (Bright Instrument Company Ltd, Cambridgeshire, UK)  onto pre-
chilled sample holders frozen in a cryotome (-30˚C) for 30 minutes (Bright Instrument Company 
Ltd, Cambridgeshire, UK). Horizontal SC layer micro dissection followed and first 15µm thick 
layer was accepted as the SC layer [47] with the remaining skin layer saved as VE for lidocaine 
quantification. The VE and dermis boundary was not possible to separate accurately as 
compared to the SC and VE boundary by cryotome dissection. 
The depth resolved mass transfer of lidocaine through the skin involved treated skin samples 
separated into the VE and systemic layer as clearance. The SC layer was discarded because 
the amount of lidocaine was found to be inconclusive and, we are primarily interested in the 
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permeation from the micro-cavities created by the MNs. There is a likelihood of parts per billion 
amounts of lidocaine that cannot be traced by HPLC-DA methods as adopted in this work. 
The VE samples were homogenised in a pestle and mortar containing pipetted 1.5 ± 0.03 ml 
deionised (DI) water (ThermoFisher Scientific, Loughborough, Leicestershire, UK) before being 
denatured in a water bath (Nickel-electro Ltd, Somerset, UK) at 60°C for 1.5 hours. 
Conceptually, lidocaine hydrochloride readily dissolved in the excess solvent water due to the 
thermolabile nature of proteins and onset of denaturation at 40°C [48]. 
After centrifugation at 4443g (8500 rpm) (Eppendorf Minispin, Hamburg, Germany), the 
supernatant was filtered using Polyethersulfone (PES) membranes (Pall Life Sciences, 
Portsmouth, UK) with a trapping MW of 1 kDa in preventing excess skin proteins and 
polypeptides contaminants accumulating with the released lidocaine. HPLC (Perkin Elmer 1200, 
Abingdon, Oxfordshire) protocol was then implemented to analyse the lidocaine allowing 
deduction of permeation kinetics [12]. This study was performed in triplicate. In addition to the 
IV studies undertaken, several synergistic characterisations were performed as discussed in the 
subsequent sub-sections. 
Determination of lidocaine diffusion in skin (D) 
The exploration of lidocaine diffusional pharmacokinetics such as apparent diffusion coefficient 
and permeation flux are obtained from Fick’s diffusion law as shown in equation (3) in mass 
terms.  
 𝐽 = −𝐷𝑖𝑖 𝑑𝑑𝑖𝑑𝑑                                           (3) 
where J is the diffusion flux (mass/cm2/s), Dim is the diffusion coefficient of species i in the skin  
(cm2/s), Ci is the concentration of active molecule, i (mass/cm3) and x is the thickness of 
membrane, skin (cm). When MNs are inserted to pierce of skin the concept is to increase the 
diffusion coefficient Dim effectively so that there is an increase in mass transfer through the SC 
into the VE layer. If this is achieved, MN ‘poke and patch’ would decrease the dependence on 
hypodermic needles and improve on the current use of creams. 
For an infinite donor solution, the concentration of active molecules in a drug vehicle is constant 
and can be expressed as in equation 4. The infinite donor method describes a practice of 
dispensing the drug on the donor area for increased reproducibility [49]. In this case, the source 
of the lidocaine is from NaCMC:gel microgels [11,12]. 
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   𝐽 =  𝐷𝑖𝑖𝐾
𝑑
𝐶𝑖                                                                                                                                (4) 
Where K is the drug’s partition coefficient between the vehicle and SC or VE layer, x is the drug 
diffusion path length [50]. Graphically, the cumulative amount of active molecule or drug 
permeated is plotted against time and the linear region of the slope in a polynomial based 
function graph is the permeation rate of drug at steady state [50]. Due to the insignificant 
number of nociceptive receptors in the SC layer, the VE and dermis (D) are defined as the 
target layers where lidocaine is required for effective anaesthetic action. A minimum therapeutic 
lidocaine concentration of 1.5µg/ml [51] is defined to be necessary in the VE and dermis layers 
for this to be the case. Separating the VE layer from the dermis is only possible through 
histological detection of the boundary between cell morphological changes. As mentioned 
earlier, the VE and dermis layer cell boundaries could not be detected uniformly and efficiently. 
The dermis layer skin thickness can vary from 200 to 350μm [52]. However, there is no distinct, 
fast procedure for VE and dermis layer boundary identification, followed by micro dissection 
according to fundamental histological changes in strata. 
RESULTS AND DISCUSSIONS 
Effects of insertion forces on MN cavities in skin 
As we mentioned earlier, we controlled the MN insertion forces directed on the skin surface to 
ensure reproducible and minimum variability of path lengths for the cavities. MN impact forces 
ranging from 3.9 – 15.7 N were used in this work. All forces were applied for five minutes 
durations and, in each case, the MNs pierced skin (Figures 2 and 3). In the figures, the dark 
blue spots were due to liquid dye pooling and increased diffusing into the MN micro cavity’s 
viable strata. The skin images did not show all of the MNs that had punctured the skin at 90˚ to 
a horizontal plane, as in a small number of cases the regular array triangular based pattern 
could not be identified (Figure 3). This effect was caused by needles not entering into the skin 
vertically due to the elastic nature and inherent roughness of the skin.  
The SC layer emerged as a dark blue band along a transverse slice of skin as highlighted by a 
yellow line (Figure 3). Initial dissecting of skin at 15µm thickness showed some blade skin 
stretching due to the applied shear forces resulting in some SC thicknesses greater than 30 µm. 
Thinner transverse slices at 5µm minimised any substantial blade stretching. An average SC 
thickness of 18.6µm was deduced. Although this is marginally larger than the 15µm 
conventional depth taken in IV studies, it was decided that due to the likelihood of minor blade 
stretching of the skin during dissection, the 15µm would be retained as the average thickness of 
the SC in this study as mentioned in several literature sources. Blade stretching effects on 5 
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micron sliced skin was fairly evident when compared with a 15µm sliced skin that resulted in up 
to 33µm SC layers. This means that the insertion forces should be designed so as to enable the 
MNs to pierce 15µm on top of the skin.  
After analysis of the skin samples (n=6) corresponding to each MN insertion force, the average 
cavity lengths corresponding to each MN insertion force are calculated which are shown in 
Figure 4. As expected, increasing the force increases the path length. A direct proportionality 
relationship between the insertion force and cavity length (e.g., doubling the force resulting in a 
doubling of cavity length) was not observed. The cavity length increased 18.4% and 15.8% from 
3.9 to 7.9 and 7.9 to 15.7 N, respectively. This suggests that increasing force decreases 
potential cutting effect through the skin. This is likely caused by a resultant force skin 
compression effect from the excess perpendicular force on the skin. As the skin compresses it 
may become more dense (e.g., higher viscoelasticity) and harder to penetrate deeper into the 
skin. In fact, the increasing force may cause more deformation of the skin. This may cause the 
entering needles to buckle and therefore they may be unable to penetrate as deeply as 
expected into the skin. Other factors have been shown to affect the size of cavities that can be 
made by MNs such as the viscoelasticity of the microgels filling the cavities. This is discussed 
further by Cheung et al. [23]. 
Optimum lidocaine NaCMC/GEL 1:2.3 microgel 
A favourable mass ratio microgel vehicle according to strong physicochemical interactions 
between NaCMC and gelatine was chosen for this study. As this paper focuses on a distinct 
area of permeation pharmacokinetics, any further microgel based optimisation studies were not 
sought after in this work. The optimum gel to NaCMC mass ratio of 2.3 for lidocaine derives 
from the previous studies on zeta potential and particle sizes by Nayak et al. [11]. This section 
expresses comparisons with particle morphology and outlines the challenge in controlling the 
loading efficiency of microgels. Lidocaine NaCMC/GEL 1:2.3 microgels were observed to be 
spherically defined and polydisperse (Figure 5). 
An average of 53% loading efficiency was deduced for lidocaine loading. In comparison to 
Nayak et al. [11] this was slightly higher. The observed microparticles range was 1.7-8.0 μm 
(Figure 5) in this work had a smaller range than in Nayak et al. [11] which would contribute a 
greater loading efficiency because of larger microparticle surface areas (Figure 5). The 
polydispersity of the applied formulation was less than that in Nayak et al. [11] because the 
difference in microgel diameter was 15 μm compared with our current study of 6.3 μm microgel 
diameter. No focus was given in controlling and reducing the microgel polydispersity in this work 
because the reduction in gelation and increase in covalent crosslinking concentrations such as 
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glutaraldehyde in the formation of polymeric microparticles may alter the current hydrogel 
properties of the formulation. 
Vertical percutaneous lidocaine permeation 
The trend on the effects of MN insertion force, cavity depths and permeation of lidocaine 
vertically (depth averaged) through the skin are discussed in this section. The VE layer is the 
main focus for lidocaine permeation because we consider this to be the target region in skin. It 
seems that a small force such as an MN impact force of 3.9N was the most favourable for 
lidocaine permeation through the vertical VE layer. A 10.2 fold increase in permeation was 
observed for a 3.9 N force at 0.25 h and similarly a 5.4 fold increase in permeation occurred at 
0.5 h compared with passive diffusional permeation (Figure 6a). 
The lidocaine permeated in the VE layer for 7.9 N and 15.7 N MN treated skin was less than the 
3.9 N treated skin. This result at first may appear to be a contradiction to increasing trends 
because the longer the cavity path length, the shorter time and greater concentration of drug in 
reaching the VE layer. However, we believe that the elasticity of the skin causes a cushioning 
effect for the MN arrays and higher MN insertion force does not necessarily allow the whole set 
of MNs in the array sequence to penetrate the skin at double or treble depths of proportional 
MN force (Figures 2 and 4). This could be worsened by a ‘bed of nails effect’ in which the MNs 
are close enough together to spread the force causing it to compress the skin rather than 
penetrating it. Once compressed, the diffusion coefficient (Dim) (equation 3) of the skin could be 
decreased, making it more difficult for the molecule to diffuse through the skin despite the 
increased path length [53]. 
The error bars representing standard deviation outline good reproducibility, especially for the 
MN permeation results up to t = 0.75 hours (samples n=3) (Figure 6). Overall, for the MN 
chosen, the smallest force (i.e. the force of 3.9 N) showed a more favourable transient 
permeation profile because of substantial increases in lidocaine in the VE layer epicentre and a 
slight plateau effect emerging just after 0.5h (Figure 6a). The largest MN insertion force, 
namely, 15.7N, also shows a favourable transient profile with respect to a plateau appearing 
after 0.25 h but the amount of lidocaine permeated in the VE layer is 2.0 and 2.8 folds less than 
the amounts observed for 3.9 N at timings of 0.25 and 0.5 hours, respectively (Figure 6a). 
The main target skin layer for local anaesthesia is the VE layer as outlined in the introduction. 
Figure 7 outlines the instantaneous lidocaine permeation profile in blood plasma clearance, 
namely, the receptor cell of FDC (n=3). The Grubb’s test [54] identified outliers from pooled data 
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sets and all outliers were eliminated. A coefficient of variance (CoV) identified other possible 
random errors (equation 5): 
CoV = SD/x�                                                                                                                 (5) 
Where SD is standard deviation and x is the arithmetic mean of data points. A threshold of upto 
30% CoV was taken to justify disregarding any data that caused significant increases in SD. 
The lowest CoV values were taken in triplicate. In cases where results were seen to be 
anomalous, it was likely to be caused by errant skin proteins that partially denatured or passed 
through the pores of the ultrafine PES membranes during the released drug filtration stage 
(permeation study section). The concentration of lidocaine (µg/ml) detected in the epicentre VE 
layer was converted to permeation based concentrations (μg/cm2) using equation (6), which 
were subsequently used to compute the diffusion coefficients according to equation 4 
Cp =  CsVA                        (6) 
Where Cp is the concentration of lidocaine permeated (μg/cm2), Cs is the concentration of 
lidocaine (µg/ml) contained in DI water as the extraction volume V (ml) and A is the surface area 
of the punched skin (cm2). 
In the VE layer of skin, all three MN insertion forces (3.9-15.7 N) (Figure 6b) helped bypassing 
the minimum lidocaine therapeutic level of 1.5 µg/ml [51]. This was achieved in a small fraction 
of 15 minutes despite the control samples appearing to reach that level slightly longer. On a dry 
skin surface, the likelihood of slow passive diffusion is a balance in stability between 
electrostatic interactions of polymers, lidocaine and covalent Schiff’s base interaction by 
glutaraldehyde [11]. With improved formulation giving a greater concentration gradient this may 
allow therapeutic levels to be reached in a relatively short period of time. 
The permeation of lidocaine into the clearance plasma compartment showed favourable trends 
for all three MN insertion forces and control within 0.75 hours (Figure 7). The smallest force of 
3.9 N showed the lidocaine crossing over the toxic plasma level of lidocaine (5 µg/ml) at a time 
of nearly one hour. Usually a range of 5 to 10 µg/ml is considered to be a toxic concentration for 
lidocaine in blood plasma [55]. 
SC layer permeation 
The SC layer has the potential to bind certain drug molecules despite not being a target region 
of lidocaine and other local anaesthetics. It is fairly important to outline if a significant amount of 
lidocaine has remained in this layer, and if not, it can then be defined that the applied lidocaine 
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has permeated into the lower skin layers [12]. In this work, the SC layer contained no lidocaine, 
irrespective of instantaneous MN treatment or PD. The results of numerous ‘no result’ and 
occasional very small (~60E-5 µg/cm2) lidocaine detected in the SC lead to CoV > 30 % and 
also high standard deviations of the results. In any case, the SC layer concentration detected 
and amount permeated retained in the SC was taken as negligible. Although the SC layer is the 
major barrier to diffusion into the skin, it does not retain large quantities of hydrophilic molecules 
in the present context. The rate limiting step appears evident in passive diffusion of lidocaine 
into the VE layer as there is a 5.2 fold permeation decrease at 0.25h as compared to MN 15.7 N 
treated skin. However, due to the lack of nociceptive receptors, anaesthesia will not be affected 
by this and minimum therapeutic levels as stated in the introduction are non-applicable. For this 
reason, the SC layer permeation will not be discussed further within this paper. 
Horizontal permeation of lidocaine in VE layer 
The horizontal permeation for lidocaine was depicted as a square apex in the VE layer which is 
outlined and explained according to MN treated skin. The mass transfer of lidocaine was 
expressed from knowing the mass released for lidocaine in excess DI water. The lidocaine 
concentration and mass transfer observed were deduced as favourable with respect to crossing 
the minimum therapeutic levels. The minimum therapeutic level of lidocaine is reported to be 
100µg/g by Zhang et al. [15].  
The aim is to understand the shortest possible lag time for horizontal permeation of lidocaine. 
The horizontal permeation colour charts of lidocaine permeating at a maximum distance of 1 cm 
from the epicentre were outlined as localised concentration (Figure 8) and mass transferred 
(Figure 9). Both figures outline completely different minimum therapeutic level trends for 
lidocaine observed in the VE layer. The mass of lidocaine was computed according to equation 
7. 
𝑀 =  𝑑𝑠𝑉
𝑀𝑡
                                          (7) 
The coefficients Cs and V are the same as in the numerator for equation 6. In the denominator, 
Mt is the calculated mass of lidocaine released from the NaCMC:gel 1:2.3 vehicle from known 
periodic timings from controlled release studies [11]. Full skin thicknesses were an average 670 
μm (± 50 μm) thick.  
When considering the concentration of lidocaine permeated in VE layer, all regimens including 
control showed horizontal permeation at minimum therapeutic levels (Figure 8). A more 
substantial concentration of horizontal permeation was observed for the smallest MN insertion 
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force (3.9 N) from 0.25 to 1 hour. This is because the same concentration range was observed 
for all four corners of the permeation square. The second most favourable horizontal 
permeation trend was observed for control as concentration equal to or greater than 10 μg/ml 
was sustained from 0.50 to 1 hour. However, as expected the horizontal permeation in skin for 
3.9 and 7.9 N forces showed greater drug concentrations in three to four corners of a square as 
compared with control (Figure 8). 
The mass transfer of lidocaine horizontally is favourable for MN treated skin at 3.9 and 7.9 N 
because of high distributions of lidocaine from 0.25 to 0.75 hours. Unlike the previous 
concentration based colour profiles (Figure 8), the horizontal diffusion (control) and permeation 
of lidocaine (MN treated 15.7 N) showed below therapeutic mass transfers of lidocaine (Figure 
9). Usually lidocaine administered by injection potentially results in faster permeation dependent 
on injection depth which is variable, initial drug volume from average loading dose of solution 
and pressure related liquid flow rates into site of delivery [15, 43]. The injection of 0.6 mL or 
greater volume of a fluid such as saline requires applied pressures greater than 1000 mmHg 
[43].   
The poke and patch method used in this study allows the pseudoplastic microgel drug to 
permeate into the micro cavities by pooling and without the need of flow. In a similar lateral 
based study by Zhang et al [15] the lidocaine mass transfer was maintained successfully for 
upto 15 minutes and two biopsied areas from a total of three showed therapeutic levels when 
considering a distance of 1 cm from the epicentre and full thickness skin up to 4000 μm. 
The partitioning, flux rate and diffusion coefficient of VE layer for lidocaine permeation 
The pharmacokinetics relating to the permeation of lidocaine affected by the MN treatment at 
the chosen forces is outlined and explained in this section. It is evident that lidocaine 
concentration for 3.9N insertion force increases after 0.25 hours as the VE layer concentration 
is increased. This is because the concentration gradient is the driving force for mass transfer 
into the clearance layer. In the last 0.25 hours of the experiment the lidocaine is permeating into 
systemic circulation at a greater concentration than in any previous time interval (Figure 7).  
The MN assisted permeation of lidocaine at the small (3.9 N) and medium (7.9 N) forces outline 
increasing partition coefficients (K), especially 3.9 N treated samples as more lidocaine is 
detected in the skin than the bipolymeric vehicle (Figure 10). Nevertheless, all three MN pierced 
skin samples outlined K for lidocaine to be significantly greater than the control samples. 
Normally K is deduced at observed steady state regions of charts at specific time duration in 
order to derive a constant K value as a point of reference. We define pseudo steady state at 
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smaller time step, and K values were calculated for different time (Figure 10). At a time over 
0.75 h the maximum partition, K of 0.58 was deduced for the 3.9 N treated samples as 
compared with other treatment technique (Figure 10). Drug based partition coefficients are 
normally fractions because the vehicle drug loaded mass is greater than the drug in a defined 
layer of skin.   
The lidocaine permeation flux outlines a very consistent increasing trend for 3.9 N treated skin 
than control and 15.7 N treated VE layer of skin (Figure 11a). As expected the flux was a lot 
higher for 3.9 N, 7.9 N and 15.7 N MN treated VE skin than control (Figure 11a). Comparatively 
the 3.9 N MN treated VE skin resulted in flux values of 13.9 and 10.5 folds greater than control 
at times of 0.25 and 0.50 hours (Figure 11a). This is because of lidocaine bypassing the rate 
limiting SC layer of MN treated skin and diffusing through the VE layer faster. The permeation 
flux for all treatment regimens in the clearance layer of skin show lower lidocaine flux rates from 
0.25 to 0.75 hours (Figure 11b). The permeation flux for 7.9 N treated skin show significantly 
greater clearance levels than control, 3.9 N and 15.7 N treated skin (Figure 11b). The likelihood 
is because of horizontal permeation as observed previously otherwise clearance flux rates 
would be just as high as VE layer flux when considering vertical permeation alone.  
The apparent diffusion coefficient derived from rearranging Fick’s first law in terms of coefficient 
D was taken from equation 4. Assuming pseudo steady state conditions, the 3.9 N treated VE 
layer outlines high lidocaine apparent D with good consistency as compared with control and 
15.7 N (Figure 12). A relatively high lidocaine apparent Dm of 0.02 cm2/h was observed for 15.7 
VE treated skin at t=0.75 hours which corresponds to the highest flux of lidocaine permeated 
(Figure 11a and 12). Like K based profiles (Figure 10), D is deduced at observed steady state in 
deriving a constant D value for reference.  
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Conclusion 
The initial assumption of a 15µm deep SC layer was confirmed as acceptable when examining 
the SC layer under microscope image gave an average of 18.6µm. Therefore the experimental 
value is in close agreement with the commonly accepted average depth of 15µm. Transverse 
skin slicing showed that even the lowest pressure of MNs impact penetrated the skin rather than 
simply deforming it. The initial premise that increasing the pressure, and therefore the force on 
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MN treatment, was confirmed when cavity length studies showed approximately 18 and 16% 
increases from 3.93 to 7.85 to 15.71N.  
In vitro studies of lidocaine diffusion gave slight mixed results as compared to passive diffusion; 
the samples treated with MNs at 3.9 N force had consistently larger concentrations of lidocaine 
in the VE layer. There was a steady increase in this concentration beyond 0.5 hours, showing a 
significantly high mass transfer drug permeation at this time. Also the increasing partition 
coefficient trend at increasing time for 3.9 N MN treated skin, VE layer, is very favourable for 
lidocaine bipolymer. In comparison to conventional creams this is a great improvement and with 
an improved formulation or a MN array that does not suggest the ‘bed of nails’ effect. 
The horizontal permeation of lidocaine from adopted regimens of passive diffusion to MN 
assisted 15.7N treatment. All regimens show complete favourable trends at therapeutic level 
above 1.5 μg/ml solely for direct concentration results without further calculations with lidocaine 
controlled release adjustments in obtaining mass transfer profiles. The passive diffusion and a 
higher MN insertion force (15.7N) are the most unfavourable regimens for horizontal permeation 
based transfer of lidocaine in VE layer. This is because the mass transfer of lidocaine is below 
the minimum predicted therapeutic mass transfer for local anaesthesia in skin. The MN assisted 
3.9N and 7.9N delivery of lidocaine horizontally in VE layer are the most favourable regimens. 
This favourability was due to lidocaine permeating at 100 μg/g and higher from 0.25 till 0.75 
hours. 
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Figure 1. Schematic diagram to show (a) the epicentre punch where the blue circle shows the 
area/size of the chosen microneedle patch, (b) the orientation of microneedle imprints in 
obtaining a slice in quantifying microcavity pathlengths, (c) prefabricated microneedles adopted 
(AdminPatch®, Sunnyvale, USA) for ‘poke and patch’ drug delivery in this work.  
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Figure 2. Typical surface images of (A) non-treated skin sample, (B) MN treated skin with insertion 
force of 3.9 N, (C) MN treated skin with insertion force of 7.9 N, (D) MN treated skin with insertion 
force of 15.7 N, all after a constant application time of 5 min. The dye (blue colour) is from Spirulina 
used in food colouring (Sainbury’s, Loughborough, Leicestershire, UK). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Typical microscope images of MN cavities (yellow circle) in micro-dissected skin for 
different MN insertion forces. 
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Figure 4: Average lengths of MN cavity in skin for different MN insertion forces (n=6 per force). 
The results show that the cavity lengths are slightly bigger than the top layer of the skin (stratum 
corneum). These are relevant for percutaneous delivery of lidocaine.  
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5: Lidocaine NaCMC/GEL 1:2.3 microgel microparticles 
  
  
Figure 6 Lidocaine permeated into VE skin layer vertically a) control and microneedle pierced 
skin at given force induced depths b) control and microneedle pierced skin crossing the minimum 
therapeutic level for lidocaine before 0.25 h.  
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Figure 7 Lidocaine clearance in control, microneedle treated skin forces (3.9 to 15.7N) and the 
toxic level for lidocaine in plasma clearance concentration.  
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Figure 8. Colour codes to outline the local area and distance for drug permeation (horizontal) in 
the VE layer of skin according to concentration of lidocaine.  
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Figure 9. Coloured contrast circles to outline the local area and distance for drug permeation 
(horizontal) in the VE layer of skin according to the mass of lidocaine 
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Figure 10. The partition coefficient (K) of lidocaine between vehicle and VE layer  
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Figure 11. The permeation flux of lidocaine in (a) VE skin layer (b) clearance compartment 
(receptor cell in Franz diffusion cell) 
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 Figure 12. The apparent diffusion coefficients of lidocaine (vertical permeation) 
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